Valuation: Amgen Inc.

Market Cap 22TCr 19TCr 18TCr 16TCr 31TCr 20,98200Cr 31TCr 2,17200Cr 84TCr 10,70400Cr 82TCr 80TCr 34,41000Cr P/E 2026 *
25.4x
P/E 2027 * 22.8x
Enterprise Value 26TCr 23TCr 22TCr 20TCr 37TCr 24,98200Cr 37TCr 2,58600Cr 1,00600Cr 12,74400Cr 97TCr 95TCr 40,97000Cr EV / Sales 2026 *
6.66x
EV / Sales 2027 * 6.28x
Free-Float
99.77%
Yield 2026 *
2.51%
Yield 2027 * 2.65%
1 day+2.59%
1 week-3.56%
Current month-3.56%
1 month+3.40%
3 months+10.44%
6 months+19.57%
Current year+24.20%
1 week 396.01
Extreme 396.01
422.8
1 month 374.46
Extreme 374.46
426.59
Current year 318.21
Extreme 318.21
447.03
1 year 288
Extreme 288
447.03
3 years 249.7
Extreme 249.7001
447.03
5 years 198.64
Extreme 198.64
447.03
10 years 133.64
Extreme 133.64
447.03
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Other

Chief Financial Officer

34,061 0.0063%
13/08/26 Exercice

Executive/Senior Manager

3,756 0.0007%
07/08/26 Free

Director

85 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+2.61%-3.56%+37.55%+49.71% 22TCr
+2.34%+1.48%+39.19%+105.37% 1,03200Cr
+1.50%-3.06%+35.86%+61.87% 61TCr
+2.11%+3.33%+16.09%+81.28% 47TCr
+0.62%-2.37%+61.93%+35.76% 35TCr
+1.94%+1.92%+23.33%+41.84% 34TCr
+1.78%-0.68%+13.29%+35.19% 27TCr
+0.90%-1.84%-5.68%+11.04% 25TCr
+2.89%-2.15%+24.89%+94.30% 18TCr
+2.98%-0.87%-33.19%-60.78% 16TCr
Average +1.86%-3.29%+21.33%+45.56% 38.79TCr
Weighted average by Cap. +1.81%-3.15%+28.09%+62.27%

Financials

2026 *2027 *
Net sales 3.89TCr 3.46TCr 3.23TCr 2.93TCr 5.54TCr 3,75400Cr 5.58TCr 39TCr 15TCr 1,91500Cr 15TCr 14TCr 6,15600Cr 4.03TCr 3.58TCr 3.35TCr 3.04TCr 5.74TCr 3,88900Cr 5.78TCr 40TCr 16TCr 1,98400Cr 15TCr 15TCr 6,37700Cr
Net income 858.05Cr 761.7Cr 712.8Cr 646.08Cr 1.22TCr 83TCr 1.23TCr 8.56TCr 3.33TCr 42TCr 3.22TCr 3.15TCr 1,35700Cr 939.28Cr 833.8Cr 780.28Cr 707.24Cr 1.34TCr 91TCr 1.35TCr 9.37TCr 3.64TCr 46TCr 3.53TCr 3.45TCr 1,48500Cr
Net Debt 4.15TCr 3.68TCr 3.45TCr 3.12TCr 5.9TCr 4,00000Cr 5.94TCr 41TCr 16TCr 2,04100Cr 16TCr 15TCr 6,56000Cr 3.58TCr 3.18TCr 2.97TCr 2.69TCr 5.09TCr 3,44900Cr 5.12TCr 36TCr 14TCr 1,75900Cr 13TCr 13TCr 5,65600Cr
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
07/26/07 $412.55 +2.47% 3,06,758
06/26/06 $402.60 -0.09% 20,36,870
05/26/05 $402.98 -0.01% 31,04,125
02/26/02 $403.04 -1.04% 35,10,312
01/26/01 $407.27 -3.38% 25,01,030
Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
402.60USD
Average target price
391.46USD
Spread / Average Target
-2.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.
  1. Stock Market
  2. Stocks
  3. AMGN Stock